ClinicalTrials.gg
CompletedNCT07236411Updated Jul 22, 2026

Absolute Bioavailability Study of Cizutamig in Healthy Adult Participants

A Phase 1 interventional study of cizutamig and Placebo in Healthy Participants Study, sponsored by Candid Therapeutics. Completed at 1 site in Australia. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-22.

Sponsored by Candid Therapeutics (part of UCB S.A.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to determine the absolute bioavailability of SC administered cizutamig in healthy adult participants.

Read the detailed description

This is a randomized, double-blind, Phase 1 study designed to determine the absolute bioavailability of SC administered cizutamig in healthy adult participants. The study will enroll participants in SC and IV cohorts.

02

Conditions studied

  • Healthy Participants Study

Keywords

  • healthy volunteer
  • pharmacokinetics
  • pharmacodynamics
  • immune system
  • cizutamig
  • T cell engager
  • bioavailability
03

In context

Lead sponsor

Candid Therapeutics is the lead sponsor of 7 studies on the registry; 4 are open to participants now.

First submitted before Candid Therapeutics became part of UCB S.A..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18-65 years of age
  2. 18-30 kg/m2 and weight 55-100 kg
  3. Individuals in good health
  4. Meets vaccination requirements as defined by the protocol
  5. Agree to abstain from consumption of alcohol within 48-hrs of study visits
  6. Agree to the use of highly effective as defined by the protocol

Exclusion criteria

Exclusion Criteria:

  1. Active Infection
  2. Inadequate clinical laboratory parameters at Screening
  3. Receipt of or inability to discontinue any excluded therapies
  4. Individuals who will decline blood products
  5. Individuals with immediate household contacts with young children (eg, ≤ 6 years old) or persons
  6. History of drug or alcohol abuse within last 12 months
  7. Individuals who are hypersensitive to intravenous immunoglobulin (IVIg)
  8. History of severe allergic or anaphylactic reactions to mAb therapy (or recombination antibody-related fusion proteins) or any constituents of study drug
  9. Major surgery requiring the use of general anesthesia within 12 weeks prior to Screening or planned or expected major surgery during the study period (from Screening to the individual's last visit)
  10. Blood donation or significant blood loss within 30 days prior to screening
  11. Individuals considered to be part of a vulnerable population (eg, incarceration)
  12. Individuals that in the opinion of the Investigator, are not suitable for participation in the trial
  13. Inability to comply with protocol-mandated requirements
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    SC injection of cizutamig

    cizutamig subcutaneous injection

    Biological: cizutamig

  • Placebo comparator
    SC injection of placebo

    placebo subcutaneous injection

    Other: Placebo

  • Experimental
    IV infusion of cizutamig

    IV cizutamig

    Biological: cizutamig

  • Placebo comparator
    IV infusion of placebo

    IV placebo

    Other: Placebo

Interventions

  • Biologicalcizutamig

    cizutamig will be dosed SC or IV according to the assigned cohort

  • OtherPlacebo

    placebo will be dosed IV or SC according to the assigned cohort

06

What researchers measure

Primary outcomes

  1. Absolute bioavailability

    Time frame: Baseline to 8 weeks

Secondary outcomes

  1. Incidence and severity of treatment-emergent adverse events through end of study

    Time frame: Baseline to 8 weeks

  2. PK parameters for cizutamig: AUC and dose-normalized AUC

    Time frame: Baseline to 8 weeks

  3. PK parameters for cizutamig: Cmax and dose-normalized Cmax

    Time frame: Baseline to 8 Weeks

  4. PK parameter for cizutamig: Tmax

    Time frame: Baseline to 8 Weeks

  5. PK parameter for cizutamig: t½

    Time frame: Baseline to 8 weeks

  6. PK Parameters for cizutamig: CL

    IV only

    Time frame: Baseline to 8 Weeks

  7. PK Parameters for cizutamig: CL/F

    SC only

    Time frame: Baseline to 8 weeks

  8. Anti-drug antibodies (ADAs)

    Time frame: Baseline to 8 weeks

  9. Changes in body temperature

    oral, tympanic, or axillary

    Time frame: Baseline to 8 Weeks

  10. Changes in ECG parameters from baseline through end of study: QRS interval

    Time frame: Baseline to 8 Weeks

  11. Changes in ECG parameters from baseline through end of study: PR interval

    Time frame: Baseline to 8 Weeks

  12. Changes in ECG parameters from baseline through end of study: QTcB

    Time frame: Baseline to 8 Weeks

  13. Changes in ECG parameters from baseline through end of study: QTcF

    Time frame: Baseline to 8 Weeks

  14. Changes in ECG parameters from baseline through end of study: QT interval

    Time frame: Baseline to 8 Weeks

  15. Changes in ECG parameters from baseline through end of study: RR

    Time frame: Baseline to 8 Weeks

  16. Changes from baseline in safety laboratory assessments through end of study: serum chemistry

    Time frame: Baseline to 8 Weeks

  17. PK Parameters for cizutamig: Vz

    IV only

    Time frame: Baseline to 8 weeks

  18. PK Parameters for cizutamig: Vss

    IV only

    Time frame: Baseline to 8 weeks

  19. PK Parameters for cizutamig: Vz/F

    SC only

    Time frame: Baseline to 8 Weeks

  20. Changes in heart rate

    Time frame: Baseline to 8 weeks

  21. Changes in respiratory rate

    Time frame: Baseline to 8 weeks

  22. Changes in blood pressure

    systolic and diastolic

    Time frame: Baseline to 8 weeks

  23. Changes in pulse oximetry

    Time frame: Baseline to 8 weeks

  24. Changes from baseline in Red Blood Cell count

    Time frame: Baseline to 8 weeks

  25. Changes from baseline in White Blood Cell count

    Time frame: Baseline to 8 weeks

  26. Changes from baseline in Platelets

    Time frame: Baseline to 8 weeks

  27. Changes from baseline in Hematocrit

    Time frame: Baseline to 8 weeks

  28. Changes from baseline in Hemoglobin

    Time frame: Baseline to 8 weeks

07

Study locations

1 site
  • Nucleus Network
    Melbourne, Victoria 3004, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2025 to primary completion in Apr 2026, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2025
First posted
Nov 19, 2025
StartActual
Dec 4, 2025
Primary completionActual
Apr 16, 2026
CompletionActual
Jul 14, 2026
Last update
Jul 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07236411
Responsible party
Sponsor
First posted
Nov 19, 2025
Start date
Dec 4, 2025
Primary completion
Apr 16, 2026
Completion
Jul 14, 2026
Last update
Jul 22, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cizutamig

Start the discussion